Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity

Gut

Volumn 66, Issue 9, 2017, Pages 1688-1696

  Bedossa, Pierre ^a   Tordjman, Joan ^b,c   Aron Wisnewsky, Judith ^b,c   Poitou, Christine ^b,c   Oppert, Jean Michel ^b   Torcivia, Adriana ^b   Bouillot, Jean Luc ^d   Paradis, Valerie ^a   Ratziu, Vlad ^e   Clément, Karine ^b,c  

^a BEAUJON HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTE; ADULT; AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BARIATRIC SURGERY; BODY COMPOSITION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FAT MASS; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRA-ABDOMINAL FAT; LIMB; LIPID STORAGE; LIPOLYSIS; LIVER BIOPSY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SUBCUTANEOUS FAT; TREATMENT INDICATION; TRUNK; ADIPOSE TISSUE; BIOPSY; COMPLICATION; LIVER; PATHOLOGY; PROCEDURES; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX FACTOR;

ADIPOSE TISSUE; AGE FACTORS; BARIATRIC SURGERY; BIOPSY; HUMANS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 84998591751     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-312238     Document Type: Article

References (36)

1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23.
2. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434–8.
3. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–19.
4. Ekstedt M, Hagstrom H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547–54.
5. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998;11:560–5.
6. Kleiner DE, Bedossa P. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. Gastroenterology 2015;149:1305–8.
7. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–21.
8. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012;56:1751–9.
9. Bedossa P, Consortium FP. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014;60:565–75.
10. Ciangura C, Bouillot JL, Lloret-Linares C, et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obesity (Silver Spring) 2010;18:760–5.
11. Ferreira I, Snijder MB, Twisk JW, et al. Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness? The Amsterdam Growth and Health Longitudinal Study. J Clin Endocrinol Metab 2004;89:2632–9.
12. Aron-Wisnewsky J, Minville C, Tordjman J, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol 2012;56:225–33.
13. Cotillard A, Poitou C, Torcivia A, et al. Adipocyte size threshold matters: link with risk of type 2 diabetes and improved insulin resistance after gastric bypass. J Clin Endocrinol Metab 2014;99:E1466–70.
14. Prat-Larquemin L, Oppert JM, Clement K, et al. Adipose angiotensinogen secretion, blood pressure, and AGT M235T polymorphism in obese patients. Obes Res 2004;12:556–61.
15. Hirsch J, Gallian E. Methods for the determination of adipose cell size in man and animals. J Lipid Res 1968;9:110–19.
16. Lassailly G, Caiazzo R, Buob D, et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 2015;149:379–88; quiz e15–6.
17. Kleiner DE, Berk PD, Hsu JY, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 2014;34:98–107.
18. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600–6.
19. Wu J, You J, Yerian L, et al. Prevalence of liver steatosis and fibrosis and the diagnostic accuracy of ultrasound in bariatric surgery patients. Obes Surg 2012;22:240–7.
20. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513–17.
21. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91–100.
22. Garcia-Monzon C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716–24.
23. Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology 2008;47:1916–23.
24. Sims EA. Are there persons who are obese, but metabolically healthy? Metab Clin Exp 2001;50:1499–504.
25. Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 2008;168:1609–16.
26. Smith U. Abdominal obesity: a marker of ectopic fat accumulation. J Clin Invest 2015;125:1790–2.
27. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009;58:1538–44.
28. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519–23.
29. Tordjman J, Divoux A, Prifti E, et al. Structural and inflammatory heterogeneity in subcutaneous adipose tissue: relation with liver histopathology in morbid obesity. J Hepatol 2012;56:1152–8.
30. Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes 2006;55:1554–61.
31. Anjani K, Lhomme M, Sokolovska N, et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatol 2015;62:905–12.
32. Spalding KL, Arner E, Westermark PO, et al. Dynamics of fat cell turnover in humans. Nature 2008;453:783–7.
33. Stern JS, Batchelor BR, Hollander N, et al. Adipose-cell size and immunoreactive insulin levels in obese and normal-weight adults. Lancet 1972;2:948–51.
34. Hoffstedt J, Arner E, Wahrenberg H, et al. Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia 2010;53:2496–503.
35. Skurk T, Alberti-Huber C, Herder C, et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 2007;92:1023–33.
36. Michaud A, Boulet MM, Veilleux A, et al. Abdominal subcutaneous and omental adipocyte morphology and its relation to gene expression, lipolysis and adipocytokine levels in women. Metab Clin Exp 2014;63:372–81.